Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

N. Nora Bennani, MD, Levi D Pederson, Pamela Atherton, Ivana Micallef, MD, Joseph P. Colgan, MD, Gita Thanarajasingam, MD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Stephen M Ansell, MD

Blood (2019) 134 (Supplement_1): 467.

https://doi.org/10.1182/blood-2019-126194

Published: 2019

Journal Articles

PD-1 Blockade with Pembrolizumab in Relapsed Low Grade Non-Hodgkin Lymphoma

Blood (2017) 130 (Supplement 1): 4055.

https://doi.org/10.1182/blood.V130.Suppl_1.4055.4055

Published: 2017

Journal Articles

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution

Saad Sirop Kenderian, Thomas M. Habermann, William R. Macon, Kay M. Ristow, Stephen M. Ansell, Joseph P. Colgan, Patrick B. Johnston, David J. Inwards, Svetomir N. Markovic, Ivana N. Micallef, Carrie A. Thompson, Luis F. Porrata, James A. Martenson, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2016) 127 (16): 1960–1966.

https://doi.org/10.1182/blood-2015-08-665505

Published: 2016

Journal Articles

Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)

Patrick B. Johnston, MD PhD, Betsy R. Laplant, MS, Ellen D. McPhail, MD, Thomas M. Habermann, MD, David J. Inwards, MD, Ivana N. Micallef, MD, Joseph P. Colgan, MD, Grzegorz S. Nowakowski, MD, Stephen Ansell, MD PhD, Thomas E. Witzig, MD

Blood (2015) 126 (23): 813.

https://doi.org/10.1182/blood.V126.23.813.813

Published: 2015

Journal Articles

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Thomas E. Witzig, Craig Reeder, Jing Jing Han, Betsy LaPlant, Mary Stenson, Han W. Tun, William Macon, Stephen M. Ansell, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Joseph P. Colgan, Svetomir Markovic, Grzegorz S. Nowakowski, Mamta Gupta

Blood (2015) 126 (3): 328–335.

https://doi.org/10.1182/blood-2015-02-629543

Published: 2015

Includes: Supplemental data

Journal Articles

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory (IMiD) Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma

Brenda Ernst, MD, Amylou Constance Dueck, PhD, Angela Toro, NP, Patrick B. Johnston, MD PhD, Thomas Haberman, MD, Jose F. Leis, MD PhD, Joseph R. Mikhael, MD, Grzegorz S. Nowakowski, MD, Joseph P. Colgan, MD, Luis F. Porrata, MD, James L Slack, MD, Stephen M. Ansell, MD PhD, Thomas E. Witzig, MD, Craig B. Reeder, MD

Blood (2014) 124 (21): 3100.

https://doi.org/10.1182/blood.V124.21.3100.3100

Published: 2014

Journal Articles

Clinical Presentation, Diagnosis, Treatment, and Outcome of Patients with Erdheim-Chester Disease: The Mayo Clinic Experience

Mithun Vinod Shah, MD PhD, Timothy G Call, MD, Carl C. Hook, MD, Patrick B. Johnston, MD PhD, Louis Letendre, MD, Joseph P. Colgan, MD, Animesh Pardanani, MBBS, PhD, Bart L. Clarke, MD, Karen L Grogg, MD, Ronald S. Go, MD

Blood (2014) 124 (21): 1405.

https://doi.org/10.1182/blood.V124.21.1405.1405

Published: 2014

Journal Articles

Dendritic Cell Vaccine Treatment for B-Cell Non-Hodgkin Lymphoma: Clinical Trial in Progress

Blood (2014) 124 (21): 4474.

https://doi.org/10.1182/blood.V124.21.4474.4474

Published: 2014

Journal Articles

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma

Luis F. Porrata, MD, Kay M. Ristow, Thomas M Habermann, MD, Thomas E Witzig, MD, Joseph P. Colgan, MD, David J. Inwards, MD, Stephen M Ansell, M.D. Ph.D., Ivana N. Micallef, MD, Patrick B. Johnston, MD, PhD, Grzegorz S. Nowakowski, MD, Carrie A Thompson, MD, Svetomir N. Markovic, MD, PhD

Blood (2013) 122 (21): 4306.

https://doi.org/10.1182/blood.V122.21.4306.4306

Published: 2013

Journal Articles

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).

Luis F. Porrata, MD, Kay M. Ristow, Thomas M Habermann, MD, Thomas E. Witzig, MD, Joseph P. Colgan, MD, David J. Inwards, MD, Stephen M Ansell, M.D., Ph.D., Ivana N. Micallef, MD, Patrick B. Johnston, MD, PhD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Svetomir N. Markovic, MD, PhD

Blood (2012) 120 (21): 2634.

https://doi.org/10.1182/blood.V120.21.2634.2634

Published: 2012

Journal Articles

Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution

Saad J. Sirop, MD, Thomas M Habermann, MD, William R Macon, MD, Kay M. Ristow, Stephen M Ansell, MD, PhD, Joseph P Colgan, MD, Patrick B. Johnston, MD, PhD, David J. Inwards, MD, Svetomir N. Markovic, MD, PhD, Ivana N. Micallef, MD, Carrie Thompson, MD, Luis F. Porrata, MD, James A. Martenson, Jr., MD, James R Cerhan, MD, PhD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD

Blood (2012) 120 (21): 1525.

https://doi.org/10.1182/blood.V120.21.1525.1525

Published: 2012

Journal Articles

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL)

Luis F. Porrata, MD, Kay M. Ristow, Thomas M. Habermann, Thomas E Witzig, Joseph P. Colgan, MD, David J. Inwards, MD, Stephen M. Ansell, M.D., Ph.D., Ivana N. Micallef, MD, Patrick B. Johnston, MD, PhD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Svetomir N. Markovic, MD, PhD

Blood (2012) 120 (21): 1527.

https://doi.org/10.1182/blood.V120.21.1527.1527

Published: 2012

Journal Articles

Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource

Brian K Link, MD, Matthew J Maurer, MS, Grzegorz S. Nowakowski, MD, Stephen M Ansell, MD, PhD, William R Macon, MD, Sergei I Syrbu, MD, Susan L Slager, PhD, Carrie A. Thompson, MD, David J. Inwards, MD, Patrick B. Johnston, MD, PhD, Joseph P. Colgan, MD, Thomas E. Witzig, MD, George J Weiner, Thomas M. Habermann, James R Cerhan, MD, PhD

Blood (2012) 120 (21): 1546.

https://doi.org/10.1182/blood.V120.21.1546.1546

Published: 2012

Journal Articles

Long Term Clinical Outcomes in Patients with Massive Splenomegaly and Non-Hodgkin's Lymphoma Treated with Splenectomy.

Jacob Smeltzer, MD, Thomas M Habermann, MD, Taner Timucin, MD, PhD, David Nagorney, MD, Kay Ristow, Joseph P Colgan, MD, Thomas E. Witzig, MD, William Harmsen, Seth Slettedahl, John Donohue

Blood (2012) 120 (21): 2692.

https://doi.org/10.1182/blood.V120.21.2692.2692

Published: 2012

Journal Articles

Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients

Stephen M. Ansell, MD, PhD, Matthew J Maurer, MS, Steven C. Ziesmer, Susan L Slager, PhD, Thomas M. Habermann, MD, Brian K Link, MD, Thomas E. Witzig, MD, David James Inwards, MD, Joseph P. Colgan, MD, James R Cerhan, MD, PhD, Anne J. Novak, Ph.D.

Blood (2011) 118 (21): 429.

https://doi.org/10.1182/blood.V118.21.429.429

Published: 2011

Journal Articles

Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,

Luis F. Porrata, MD, Kay M. Ristow, Joseph P. Colgan, MD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, David James Inwards, MD, Stephen M. Ansell, MD, PhD, Ivana N. Micallef, MD, Patrick B. Johnston, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Svetomir N. Markovic, MD, PhD

Blood (2011) 118 (21): 3642.

https://doi.org/10.1182/blood.V118.21.3642.3642

Published: 2011

Journal Articles

The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma

Ryan A. Wilcox, MD, PhD, Kay M. Ristow, Thomas M. Habermann, MD, David J Inwards, MD, Ivana N. Micallef, MD, Patrick B. Johnston, Joseph P. Colgan, MD, Grzegorz S. Nowakowski, MD, Stephen M. Ansell, MD, PhD, Thomas E. Witzig, MD, Svetomir N. Markovic, MD, PhD, Luis F. Porrata, MD

Blood (2011) 118 (21): 85.

https://doi.org/10.1182/blood.V118.21.85.85

Published: 2011

Journal Articles

Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies

Shaji Kumar, MD, Joseph R. Mikhael, MD, Betsy R. LaPlant, Joseph P. Colgan, MD, David James Inwards, MD, Patrick B. Johnston, Kristina Laumann, Ivana N. Micallef, MD, Grzegorz S. Nowakowski, Stephen M. Ansell, M.D., Ph.D., Kelly Curtis, MD, Angela Dispenzieri, MD, Martha Q Lacy, MD, Jose F. Leis, MD, PhD, Donald Northfelt, MD, Craig B. Reeder, MD, James L. Slack, MD, Thomas E. Witzig, MD

Blood (2011) 118 (21): 2682.

https://doi.org/10.1182/blood.V118.21.2682.2682

Published: 2011

Journal Articles

Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,

Blood (2011) 118 (21): 3652.

https://doi.org/10.1182/blood.V118.21.3652.3652

Published: 2011

Journal Articles

Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients

Robin R. Klebig, MSN, CNP, Stephen M. Ansell, MD, PhD, Joseph P. Colgan, MD, Dennis A. Gastineau, MD, Thomas M. Habermann, MD, Patrick B. Johnston, Svetomir N. Markovic, MD, PhD, Ivana N. Micallef, MD, Grzegorz S. Nowakowski, MD, Luis F. Porrata, MD, Kay M. Ristow, Carrie A. Thompson, MD, Jessica N. Towns, PA-C, Thomas E. Witzig, MD, David J. Inwards, MD

Blood (2011) 118 (21): 1926.

https://doi.org/10.1182/blood.V118.21.1926.1926

Published: 2011

NARROW

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

PD-1 Blockade with Pembrolizumab in Relapsed Low Grade Non-Hodgkin Lymphoma

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution

Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory (IMiD) Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma

Clinical Presentation, Diagnosis, Treatment, and Outcome of Patients with Erdheim-Chester Disease: The Mayo Clinic Experience

Dendritic Cell Vaccine Treatment for B-Cell Non-Hodgkin Lymphoma: Clinical Trial in Progress

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).

Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution

Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL)

Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource

Long Term Clinical Outcomes in Patients with Massive Splenomegaly and Non-Hodgkin's Lymphoma Treated with Splenectomy.

Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients

Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,

The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma

Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies

Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,

Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only